2008-006381-29: Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer |
|
|
| Ongoing | 2 | 200 | Europe | Docetaxel, 5-Fluorouracil, Cyclophosphamide, Epirubicin, Taxotere, Fluorouracil, Endoxan, Farmorubicin, Taxotere, Fluorouracil, Endoxan, Farmorubicin | Universitätsmedizin Mainz | Eligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflammatory disease. Metastatic disease is excluded. All patients will be treated with 3 cycles Docetaxel and 3 cycles FEC. | | | | |
